Walleye Capital’s NovoCure NVCR Stock Holding History
Bought
Maintained
Sold
Other funds holding NVCR
SCM
VPM
VCM
QCM
Walleye Capital's NVCR Position: Q1 2026 in Review
Walleye Capital sold out of NovoCure (NVCR) in Q1 2026, closing a stake of 11,676 shares — an estimated $151K sold.
Walleye Capital first reported a position in NVCR in Q1 2019 and held it in 16 quarters. The position peaked at $2.8M in Q3 2025. 222 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.
- Walleye Capital reported no remaining NovoCure position as of Q1 2026 after selling out during the quarter.
- Walleye Capital sold 11,676 NovoCure shares in Q1 2026, an estimated $151K.
- Walleye Capital first reported a position in NovoCure in Q1 2019 and held it in 16 quarters.
- Walleye Capital's NovoCure position peaked at $2.8M in Q3 2025.
- 222 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.
Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.